AIC gets approval to market implants in Europe.

Active's implants react to the body's movements in a way which enables them to mimic the flexibility of the original cartilage.

Active Implant Corporation (AIC), which is developing orthopedic implants, has completed clinical trials for its flagship product and received CE Mark certification which allows it to market the product in Europe. AIC is registered in Delaware, USA, its headquarters are located in Tennessee, where most of its investors also reside, and it has a development center in Netanya. The company is currently beginning gradual marketing in Europe. AIC was founded in Israel in 2004 by chairman and VP technology Amiram Steinberg, one of the founders of Impliant Ltd. (formerly Limber Ltd.) and DISCure Ltd.

The company's products are polymer implants intended for orthopedic use as substitutes for bone and cartilage. Active's implants react to the bodies movements in a way which enables them to mimic the flexibility of the original cartilage. The product which was approved is an implant intended for the hip-joints.

A number of months ago, AIC reported the completion of its first financing round, in which it raised $10 million, mostly from private strategic investors from Tennessee.

Published by Globes [online], Israel business news - www.globes.co.il - on September 19, 2006

© Copyright of Globes Publisher Itonut (1983) Ltd. 2006

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס